Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01139047
Other study ID # US10160
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date June 2010
Est. completion date June 2010

Study information

Verified date September 2012
Source Galderma R&D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.


Recruitment information / eligibility

Status Completed
Enrollment 77
Est. completion date June 2010
Est. primary completion date June 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Healthy male and female adults (ages 18 years or older) - Subjects with healthy skin as determined by the clinical grader Exclusion Criteria: - Subjects with a degree of skin pigmentation that interferes with the reading of skin reactions - Subjects with known allergy to one of the components of the study drugs (refer to the package inserts for MetroGel® 1% and Finacea® Gel 15%) - Subjects who have participated in another investigational drug or device research study within 30 days of enrollment - Subjects with a washout period for topical treatment on the treated area less than 1 week for corticosteroids and/or 4 weeks for retinoids - Subjects with a washout period for systemic treatment less than 1 week for medications that may increase photosensitivity and/or 4 weeks for corticosteroids and/or 6 months for retinoids - Subjects with current sunburn, eczema, atopic dermatitis, perioral dermatitis, rosacea, or other topical conditions on the area to be treated - Subjects who foresee unprotected and intense UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
metronidazole 1% gel
Apply topically once daily on one side of the face for three weeks
azelaic acid 15% gel
Apply topically twice daily on the opposite side of the face for three weeks

Locations

Country Name City State
United States Thomas J. Stephens & Associates, Inc. Colorado Springs Colorado

Sponsors (1)

Lead Sponsor Collaborator
Galderma R&D

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3 Number of participants who were a success with regard to worst post-baseline tolerability scores in each of the tolerability assessments at any time point between baseline and week 3. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0. baseline to week 3
Secondary Number of Participants Who Were a Success With Regard to Worst-baseline Tolerability Assessment Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) on Day 22 Number of participants who were a success with regard to worst-baseline tolerability assessment scores for each assessment (erythema, scaling, dryness, stinging/burning) on day 22. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0 for each assessment. day 22
Secondary 6 Question Subject Preference Survey at Week 3 Number of participants per response to each question of the subject preference survey at week 3 3 weeks
See also
  Status Clinical Trial Phase
Completed NCT05597254 - Facial Skin Clinical and Microbial Profiling From Oral Probiotic Supplementation N/A
Active, not recruiting NCT06140628 - A 28-day Clinical Study on Facial Skin Rejuvenation N/A
Completed NCT04154436 - Effectiveness, Safety, and Cost Efficacy of Water (H2O) as a Substitute for Sodium Bicarbonate (NaHCO3) Plus Solution in Neutralization of Chemical Peeling Using 35% Glycolic Acid Solution N/A
Withdrawn NCT02787356 - Standard TDS Irritation Study: Trained Skin Grader vs. Digital Imaging N/A
Completed NCT04449159 - Efficacy of Vinh Wellness Collagen on Skin Health N/A
Enrolling by invitation NCT06188338 - A 56-day Clinical Study on Facial Skin Rejuvenation N/A
Completed NCT01139008 - Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin Phase 4
Completed NCT05094687 - Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).
Recruiting NCT05235997 - Placebo Controlled Efficacy Evaluation of the Hydrolyzed Collagen Peptide In Adult Females N/A
Completed NCT01046565 - Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin Phase 1
Completed NCT01046396 - Tolerability Comparison of Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin Phase 1
Completed NCT04701463 - A Specialized Amino Acid Mixture on Body Composition and Skin State in Overweight and Obese Class I Postmenopausal Women N/A
Completed NCT02422836 - Tolerability and Efficacy of Anti-Aging Treatment Regimen in Subjects With Photodamage N/A
Completed NCT04002856 - Aesthetic Performance of "Profhilo®" Injective Intradermal Treatment for the Neck N/A
Completed NCT03873896 - The Skin Wrinkle Test: a Simple Clinical Test of Regional Block Success N/A
Completed NCT03505684 - Effect of Oral Collagen Tripeptide on Skin Moisture and Wrinkles in Adult Women N/A
Active, not recruiting NCT06152718 - New Regenerative Approach for Dermal Renovation (Karisma)
Recruiting NCT04344119 - Assessment of Chilbains Occuring During Covid-19 Infection
Recruiting NCT06291415 - The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) Phase 1
Completed NCT05872178 - Omegia Softgel Clinical Research Program N/A